Teva OK'd for AZ's Symbicort generic; Sun OK'd for generic of Roche's Boniva; Endocrine Society warns about testosterone enhancers;

Pharma News

@FiercePharma: ICYMI: WHO reports success in distributing vaccines at ambient temperatures. Story via FierceVaccines. | Follow @FiercePharma

@EricPFierce: GSK could get some financial breathing room with an EU nod for Anoro. Story | Follow @EricPFierce

@CarlyHFierce: Tops on the old FP site yesterday: Reuters: Bayer, Novartis, Reckitt eye $10B-$12B bids for Merck consumer unit. Story  | Follow @CarlyHFierce

> Frost & Sullivan is predicting fast growth of diabetes drugs in Latin America. Story

> Teva Pharmaceutical Industries ($TEVA) has gotten EU approval for a generic that will put pressure on AstraZeneca's blockbuster Symbicort. Story

> Novartis ($NVS) has won approval of its eye drug Lucentis for a fourth indication in Japan. Release

> The Endocrine Society has issued a statement saying men should understand the risks of taking testosterone-raising drugs and pointing out that low testosterone is not a disease, only a number. Story

> Bank of America Merrill Lynch and Mizuho Bank are leading the $7 billion financing behind Actavis' ($ACT) acquisition of Forest Laboratories. ($FRX). Story

> India's Sun Pharma has gotten FDA approval to make a generic of Roche's osteoporosis drug Boniva, the first drugmaker to get an OK for the product. Item

Medical Device News

@FierceMedDev: At J&J's Coridis, at least, renal denervation is continuing to advance. Press release. | Follow @FierceMedDev

@MarkHFierce: I spoke to Daktari Diagnostics' CEO about the company's Series D fundraising efforts. Story via FierceDiagnostics | Follow @MarkHFierce

@MichaelGFierce: BioMérieux's BioFire sets course for GI panel FDA clearance. Article | Follow @MichaelGFierce

@GalenMoore: Sham surgeries: Medtech's placebos? Or a waste of money at patients' risk? via Forbes | Follow @GalenMoore

> Myriad touts positive data for Dx that predicts prostate cancer recurrence. More

> Wall Street cools to CryoLife's new guidance. Story

Biotech News

@FierceBiotech: Belgian UCB gets ready for CEO change plus more career changes in biopharma in this week's Chutes & Ladders. | Follow @FierceBiotech

@JohnCFierce: Merck KGaA has the firepower to pull off a big buyout, but will it? Story | Follow @JohnCFierce

@DamianFierce: Ariad's new board member is an activist investor with a history of pushing companies to sell. More | Follow @DamianFierce

@EmilyMFierce: Gene therapy regenerates damaged tissue in pigs after heart attack. Story from FierceBiotech Research | Follow @EmilyMFierce

> EU breathes hope into GlaxoSmithKline's latest respiratory contender. Article

> Isis gears up for Phase III with Biogen-partnered antisense drug. News

And Finally... There has been an upsurge this year in young adults and middle-aged people getting the flu in the U.S., and dying from it, even after vaccine makers have brought a host of new products to market. Story

Suggested Articles

The company will commit $300 million over the next five years to hire more people of color and increase clinical trial diversity.

Moderna, after tapping almost $1 billion in federal funding, agreed to deliver 100 million doses of its vaccine candidate for up to $1.5 billion.

FDA advisors will question the clinical data and manufacturing for Mesoblast's Ryoncil, a cell therapy for pediatric acute graft vs. host disease.